275 related articles for article (PubMed ID: 22491019)
1. Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.
Martis S; Peter I; Hulot JS; Kornreich R; Desnick RJ; Scott SA
Pharmacogenomics J; 2013 Aug; 13(4):369-77. PubMed ID: 22491019
[TBL] [Abstract][Full Text] [Related]
2. Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians.
Suarez-Kurtz G; Genro JP; de Moraes MO; Ojopi EB; Pena SD; Perini JA; Ribeiro-dos-Santos A; Romano-Silva MA; Santana I; Struchiner CJ
Pharmacogenomics J; 2012 Jun; 12(3):267-76. PubMed ID: 21173785
[TBL] [Abstract][Full Text] [Related]
3. Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations.
Pedersen RS; Brasch-Andersen C; Sim SC; Bergmann TK; Halling J; Petersen MS; Weihe P; Edvardsen H; Kristensen VN; Brøsen K; Ingelman-Sundberg M
Eur J Clin Pharmacol; 2010 Dec; 66(12):1199-205. PubMed ID: 20665013
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population.
Kudzi W; Dodoo AN; Mills JJ
BMC Med Genet; 2009 Dec; 10():124. PubMed ID: 19954515
[TBL] [Abstract][Full Text] [Related]
5. Similarity in recombination rate and linkage disequilibrium at CYP2C and CYP2D cytochrome P450 gene regions among Europeans indicates signs of selection and no advantage of using tagSNPs in population isolates.
Pimenoff VN; Laval G; Comas D; Palo JU; Gut I; Cann H; Excoffier L; Sajantila A
Pharmacogenet Genomics; 2012 Dec; 22(12):846-57. PubMed ID: 23089684
[TBL] [Abstract][Full Text] [Related]
6. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
7. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.
Hamdy SI; Hiratsuka M; Narahara K; El-Enany M; Moursi N; Ahmed MS; Mizugaki M
Br J Clin Pharmacol; 2002 Jun; 53(6):596-603. PubMed ID: 12047484
[TBL] [Abstract][Full Text] [Related]
8. A Novel CYP2C-Haplotype Associated With Ultrarapid Metabolism of Escitalopram.
Bråten LS; Haslemo T; Jukic MM; Ivanov M; Ingelman-Sundberg M; Molden E; Kringen MK
Clin Pharmacol Ther; 2021 Sep; 110(3):786-793. PubMed ID: 33759177
[TBL] [Abstract][Full Text] [Related]
9. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T
Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147
[TBL] [Abstract][Full Text] [Related]
10. Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity.
Dandara C; Lombard Z; Du Plooy I; McLellan T; Norris SA; Ramsay M
Pharmacogenomics; 2011 Dec; 12(12):1663-70. PubMed ID: 22118051
[TBL] [Abstract][Full Text] [Related]
11. CYP2C9 allelic variants: ethnic distribution and functional significance.
Xie HG; Prasad HC; Kim RB; Stein CM
Adv Drug Deliv Rev; 2002 Nov; 54(10):1257-70. PubMed ID: 12406644
[TBL] [Abstract][Full Text] [Related]
12. Distribution of CYP2C9*13 allele in the Chinese Han and the long-range haplotype containing CYP2C9*13 and CYP2C19*2.
Si D; Wang J; Zhang Y; Zhong D; Zhou H
Biopharm Drug Dispos; 2012 Sep; 33(6):342-5. PubMed ID: 22886551
[TBL] [Abstract][Full Text] [Related]
13. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms.
Yasar U; Lundgren S; Eliasson E; Bennet A; Wiman B; de Faire U; Rane A
Biochem Biophys Res Commun; 2002 Nov; 299(1):25-8. PubMed ID: 12435384
[TBL] [Abstract][Full Text] [Related]
14. Inactive alleles of cytochrome P450 2C19 may be positively selected in human evolution.
Janha RE; Worwui A; Linton KJ; Shaheen SO; Sisay-Joof F; Walton RT
BMC Evol Biol; 2014 Apr; 14():71. PubMed ID: 24690327
[TBL] [Abstract][Full Text] [Related]
15. CYP2C9 and CYP2C19 Allele and Haplotype Distributions in Four Mestizo Populations from Western Mexico: An Interethnic Comparative Study.
Saldaña-Cruz AM; León-Moreno LC; Sánchez-Corona J; Santiago DA; Mendoza-Carrera F; Castro-Martínez XH; García-Zapién AG; Morán-Moguel MC; Flores-Martínez SE
Genet Test Mol Biomarkers; 2016 Nov; 20(11):702-709. PubMed ID: 27617498
[TBL] [Abstract][Full Text] [Related]
16. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation.
Chang TK; Yu L; Goldstein JA; Waxman DJ
Pharmacogenetics; 1997 Jun; 7(3):211-21. PubMed ID: 9241661
[TBL] [Abstract][Full Text] [Related]
17. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.
Scott SA; Khasawneh R; Peter I; Kornreich R; Desnick RJ
Pharmacogenomics; 2010 Jun; 11(6):781-91. PubMed ID: 20504253
[TBL] [Abstract][Full Text] [Related]
18. Distribution of polymorphisms in the CYP2C9 gene and CYP2C19/CYP2C9 haplotypes among Venezuelan populations.
Flores-Gutiérrez S; Rodríguez-Larralde Á; Vívenes de Lugo M; Castro de Guerra D
Ann Hum Biol; 2017 Mar; 44(2):191-198. PubMed ID: 27230833
[TBL] [Abstract][Full Text] [Related]
19. Distribution of CYP2C19*17 allele and genotypes in an Indian population.
Anichavezhi D; Chakradhara Rao US; Shewade DG; Krishnamoorthy R; Adithan C
J Clin Pharm Ther; 2012 Jun; 37(3):313-8. PubMed ID: 21916910
[TBL] [Abstract][Full Text] [Related]
20. Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory.
Strom CM; Goos D; Crossley B; Zhang K; Buller-Burkle A; Jarvis M; Quan F; Peng M; Sun W
Genet Med; 2012 Jan; 14(1):95-100. PubMed ID: 22237437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
